That prostigmin relieves the muscular weakness of myasthenia gravis has now been accepted quite generally by all observers who have studied the drug.1 This relief, furthermore, has provided new insight into the mechanisms at fault in the disease. The possibility of using the response to prostigmin as a diagnostic test of myasthenia has not, however, been fully appreciated. It is true that Viets and Schwab2 have found that the weakness due to lesions of the central and peripheral nervous system was not materially improved. However, the effect of prostigmin on the muscular diseases has not been systematically studied. We have accordingly examined the action of the drug on the weakness due to a variety of diseases of the muscular system. None of the patients obtained any striking relief from prostigmin. Therefore myasthenia gravis is the only condition examined thus far in which muscular weakness is consistently and markedly
GAMMON GD, SCHEIE H. USE OF PROSTIGMIN AS A DIAGNOSTIC TEST OF MYASTHENIA GRAVIS. JAMA. 1937;109(6):413–414. doi:10.1001/jama.1937.02780320015005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: